(Q34351993)

1 August 2017

title

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings (English)

1 reference

1 August 2017

1 reference

15

Keikawus Arastéh

0 references

Schlomo Staszewski

12

object named as

Schlomo Staszewski

0 references

author name string

Hartmut Stocker

1

1 reference

1 August 2017

Charlotte Kloft

2

1 reference

1 August 2017

Nele Plock

3

1 reference

1 August 2017

Antje Breske

4

1 reference

1 August 2017

Guido Kruse

5

1 reference

1 August 2017

Christian Herzmann

6

1 reference

1 August 2017

Hubert Schulbin

7

1 reference

1 August 2017

Peter Kreckel

8

1 reference

1 August 2017

Christoph Weber

9

1 reference

1 August 2017

Frank Goebel

10

1 reference

1 August 2017

Joerg Roeling

11

1 reference

1 August 2017

Schlomo Staszewski

12

1 reference

1 August 2017

Andreas Plettenberg

13

1 reference

1 August 2017

Christiane Moecklinghoff

14

1 reference

1 August 2017

Keikawus Arastéh

15

1 reference

1 August 2017

Michael Kurowski

16

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Antimicrobial Agents and Chemotherapy

1 August 2017

published in

1 reference

1 August 2017

volume

50

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

667-673

1 reference

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Pathophysiology of body composition and metabolic abnormalities in HIV-infection: therapeutic implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting

6 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

6 July 2018

12 December 2020

Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Growth hormone, fatigue, poor sleep, and disability in HIV infection

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1366872

Endocrine function in the HIV wasting syndrome

27 October 2018

1 reference

12 December 2020

Increased tumor necrosis factor-alpha serum levels in patients with HIV wasting syndrome and euthyroid sick syndrome

1 reference

12 December 2020

Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system

1 reference

12 December 2020

Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

10.1128/AAC.50.2.667-673.2006

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference